Preliminary study of the fibrin structure in hypertensive, dyslipidemic and type 2 diabetic patients

Rita Marchi-Cappelletti1, Nuris Suárez-Nieto

  • 1Instituto Venezolano de Investigaciones Científicas, Centro de Medicina Experimental, Laboratorio de Fisiopatología, Sección Biología del Desarrollo de la Hemostasia, Caracas, Venezuela. rmarchi@ivic.gob.ve

Investigacion Clinica
|February 10, 2011
PubMed

Insights

Fibrin structure is altered in dyslipidemia and type 2 diabetes patients, impacting cardiovascular disease risk. These changes affect fibrin network porosity and elasticity, suggesting a need for further investigation into metabolic disease impacts on blood clotting.

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Metabolic Diseases

Background:

  • Individuals with hypertension, dyslipidemia, or diabetes face elevated cardiovascular disease (CVD) risk.
  • Impaired fibrin structure and function may exacerbate CVD risk in these patient groups.

Purpose of the Study:

  • To investigate fibrin network and degradation properties in patients with hypertension (HT), dyslipidemia (DL), and type 2 diabetes mellitus (T2D).
  • To compare these properties against a control group of healthy individuals.

Main Methods:

  • Fibrinogen concentration measured by gravimetric method.
  • Fibrin network formation and porosity assessed via turbidity and permeation.
  • Fibrin elastic properties evaluated by compaction; fibrin lysis assessed by turbidity after tPA addition.

Main Results:

  • Fibrinogen concentration was significantly higher only in T2D patients.
  • Fibrin polymerization and lysis were similar across all groups.
  • Permeation was significantly slower in DL and T2D patients; compaction coefficient was smaller in T2D patients.

Conclusions:

  • Fibrin structure is altered in dyslipidemia and T2D patients.
  • Altered fibrin structure may be linked to increased cholesterol (DL) and glycation (T2D).
  • These findings highlight potential mechanisms contributing to increased CVD risk in metabolic diseases.